Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA to guide changes in standard of care chemotherapy

Phase 2 trial in metastatic HER2-negative or triple-negative breast cancer whose title states that ctDNA is used to guide changes in chemotherapy. The registry primary outcome is progression-free survival. ClinicalTrials.gov lists the study as recruiting.

Vanderbilt-Ingram Cancer Center